# 4D Molecular Therapeutics begins Phase 3 enrollment for eye gene therapy

_Published Wednesday, September 30, 2026 at 10:19 PM EDT · Science · Latest · Tier 2 — Notable_

![4D Molecular Therapeutics begins Phase 3 enrollment for eye gene therapy — Primary](https://s.yimg.com/cv/apiv2/cv/apiv2/social/images/yahoo-finance-default-logo.png)

4D Molecular Therapeutics has begun enrolling patients in its 4SIGHT Phase 3 trial of 4D-150 for diabetic macular edema, according to a B. Riley Securities research update. Two other Phase 3 trials are evaluating the gene therapy for wet age-related macular degeneration.

The treatment is designed to continuously produce an anti-VEGF protein, potentially reducing repeated eye injections. Two-year SPECTRA results showed a 10.8-letter vision gain and an average of 5.2 supplemental injections after three aflibercept loading doses at the Phase 3 dose. No intraocular inflammation or ocular serious adverse events were reported across the 22-patient study population.

## Sources

- [Yahoo Finance](https://finance.yahoo.com/healthcare/articles/top-biotech-stock-pick-b-212417924.html)

---
Canonical: https://techandbusiness.org/newswire/UdDS_RgPvpxP2kdi0cPK7d
Published: 2026-10-01T02:19:58.776Z
Story chronology: 2026-09-29T21:24:17.000Z
Retrieved: 2026-10-01T04:34:20.205Z
Publisher: Tech & Business (techandbusiness.org)